Results: Only LRRs was found in 20 patients [17 papillary and 3 follicular] with diagnostic accuracy of FDG PET/CT of 100 %. 14/20 patients belonged to HMA where surgical neck exploration was done while in the remaining 6 patients with LMA empirical high dose of radioactive iodine-131 was given based on the assumption of the presence of a mixture of undifferentiated and differentiated thyroid cancer cells; though their post-therapy scan was negative but declined TGlevels were elicited in their follow-up [base-line 27.7±2.4 and at follow-up 6.8±1.4 ng/ml; P 0.02].
INTRODUCTION
Differentiated thyroid cancer [DTC] occurs in 3-5 per 100,000 people and represents about 1% of all malignant tumors [1] . In most cases, prognosis is favorable and treatment consists of primary surgery followed by ablative radioiodine administration with a 10-y survival rate of 80%-90% [2, 3] . However, special subgroups of patients demonstrate a less favorable course of disease with much lower survival rates where poor radioiodine accumulation is usually associated [4] and presence of distant metastasis [5] . Patients with DTC may have only iodine-negative tumor lesions or both iodine-negative and iodine-positive tumor tissue [4, 6] . Consequently, the presence of iodine-negative tumor tissue decreases the accuracy of iodine scintigraphy. This can lead to the situation in which tumor tissue is not detected by iodine scintigraphy and will remain without further treatment [7] .
Such a group had less or de-differentiated thyroid cancer cells, which are more aggressive in their clinical behavior and have a high glucose metabolism and FDG uptake [8] .
*Address correspondence to this author at the Nuclear Medicine Department, Faculty of Medicine, Cairo University, Post address: 32, Soliman Abaza St. Al-Mohandeseen, 11123, Giza, Egypt; Tel: +2-010-1648583; Fax: +20233-44-45; E-mail: amramin67@gmail.com Hence, 18F-FDG PET enables detection and precise localization of loco-regional recurrence and distant metastases in such patients with significant impact on patients' management, therefore, it was recommended as a routine diagnostic tool [7, 9] . 18F-FDG PET for DTC has concentrated on patients with negative radioiodine scintigraphy and increased thyroglobulin (TG). Iagaru and Razfar et al. studies [10, 11] demonstrated a significant difference in the mean TG in patients with positive vs negative FDG PET-CT while Hamy et al. [12] recommended cervical re-exploration in patients with persistently elevated TG as regional recurrence is highly predicted. FDG PET-CT allows anatomical localization of non-131 I-avid surgically resectable tumors and preventing un-necessary surgical exploration with sensitivities and specificities of 85% and 94% respectively [7, [13] [14] [15] [16] together with its ability to detect unrecognized distant metastatic disease.
If iodine-negative tumor sites exist in addition to iodinepositive sites, the benefit of further radioiodine therapy is questionable [17, 18] . The importance of FDG PET-CT lies in the fact that thyroid cancer cells in patients with negative 131I result are usually more poorly or de-differentiated. As stated earlier, poorly or de-differentiated thyroid cancer cells may not take up 131I, thus making them not amenable for high dose 131I therapy [19] . We have an assumption that a mixture of de-and differentiated cancer cells might co-exist and the former cells will induce FDG uptake while the latter though are amenable for 131I uptake but are beyond scintigraphic resolution and can induce lower FDG uptake. Hence, we proposed in this study the term low metabolic activity [LMA] lesions to describe our suggestion and to evaluate the 131I usefulness in such situations.
MATERIALS AND METHODS

Patients and Design of Study
This prospective study was approved by the local ethics committee of the scientific review board of Cairo University and informed consent was obtained from all participants according to the Helsinki Declaration of 1964, amended in 1975 and 1983, of the World Medical Association. We included patients with DTC who were suspected of having cervical iodine-negative tumor tissue. Each patient had to meet the following inclusion criteria: elevated TG level in the euthyroid and also the hypothyroid state (>2ng/mL) or morphologically suspected tumor disease (sonography, CT, MRI), L-thyroxin withdrawal for 4 weeks before 131-I whole-body scintigraphy, thyroid-stimulating hormone increase of >30 mU/L, performance of 131I whole-body scintigraphy meeting highquality requirements with decision of a nuclear medicine physician that no pathologic accumulation of radioiodine could be detected on whole-body scintigraphy, previous total thyroidectomy and radioiodine ablation. Exclusion criteria were: positive test for TG antibodies, administration of CT-contrast within the last 6 months, positive iodine urine test performed on the day of scintigraphy, pregnancy, or an age less than 18 y and those with distant metastasis to bones, lungs, brain or elsewhere. FDG PET/CT was compared with histopathology [Post-surgical excision] and follow-up results as a gold standard. All data were acquired with a combined PET/CT in-line system [Biograph; Siemens Medical Solutions]. This system integrates a PET scanner (Ecat HR1; Siemens) with a dual-section helical CT scanner [Somatom; Siemens] and allows the acquisition of coregistered CT and PET images in one session.
Imaging Modalities
Diagnostic 131-I Scan Acquisition Protocol
131-I in doses of 185 MBq [5mCi]
were given orally to all patients and they were scanned at a mean of 48.3±1.0 h later. The diagnostic scanning included anterior and posterior wholebody images with spot anterior views of the neck. The scans were obtained with large field-of-view dual-head gamma cameras (Philips-Axis, Eindhoven, the-Netherlands) mounted with a high-energy parallel-hole collimator. All scans were obtained with a 20% energy window centered at 364 keV. Anterior and posterior whole-body scans were obtained with the patient supine using a 256x256 matrix and an 8.75 cm/min scanning speed, whereas the spot view was obtained using a large field of view and a 256x256 matrix for 10 min/view.
18F-FDG PET/CT Acquisition Protocol
The patients fasted at least 4 h before injection of 370 MBq 18F-FDG. Scanning was started 60-90 min after the injection [5-7 bed positions; acquisition time, 5 min/bed position]. Blood glucose levels did not exceed 150 mg/dL [8.3 mmol/L]. No intravenous contrast agent was administered. Initially, patients were examined in the supine position with arms elevated, and CT scanning was started at the level of the Cervico-thoracic region with the following parameters: 40 mAs; 130 kV; slice thickness, 2.5 mm; pitch, 1.5. The CT scans were acquired during breath holding within the normal expiration position and reached caudally to the mid-thigh. PET over the same region was performed immediately after acquisition of the CT images [5 min/bed position]. Afterward, a second data acquisition set from the base of the skull to the upper thoracic region was initiated with the patient's arms positioned next to the body. For this second part of the examination, the same parameters were used for CT and PET. The CT data were used for attenuation correction, and images were reconstructed as 5-mm slices applying a standard iterative algorithm.
FDG PET CT Interpretation
Images were interpreted at a workstation equipped with fusion software [Syngo; Siemens] that provides multi-planar reformatted images and enables display of the PET images [with and without attenuation correction], CT images, and fused PET/CT images in any percentage relation. Analysis of images was performed as a multistep image interpretation [20] . During the first step of analysis, PET/CT and CT images were scored blindly and independently by 2 nuclear medicine physicians and 2 radiologists. For this purpose, we adopted the diagnostic scale of Palmedo et al. [4] .
A lesion was considered as true-positive if the score was 2-4 and if histopathology was positive or if it showed progression at follow-up sessions. Findings were considered as true-negative if histology was negative or if follow-up examinations did not show any progression in the region of concern for at least 12 months. A lesion was considered as false-positive if histopathology was negative or if it showed no progression at follow-up sessions. Those considered as false-negative if histology was positive or if follow-up examinations showed growth of the lesion(s) [4] . Follow-up examinations were performed every 3-6 months and included measurement of TG levels. The terms of locoregional recurrence [either in the thyroid bed or cervical adenopathy or both] were used. In our study, in the analysis of FDG PET/CT the term LMA was used to describe those with maxSUV ≤5 where we assume a mixture of de-and differentiated cells in cervical lesions could be present, while those >5 termed High metabolic activity [HMA] .
Therapeutic Procedure
After FDG PET/ imaging-based localization of active lesions; surgical excision was carried out in HMA cases. Those with LMA lesions were shifted to empirical high dose of I131 therapy [150 mCi].
Statistical Analysis
Data were statistically described in terms of mean ± standard deviation (±SD), median and range, or frequencies (number of cases) and percentages when appropriate. ANOVA was used for statistical comparative analysis. The diagnostic accuracy of PET/CT was calculated on the basis of the true-positive and true-negative findings as described. P value less than 0.05 was considered significant althrough.
RESULTS
Patients' Population
Forty patients were included in the study. The age of our patients ranged 22- Patients with DTC have a less favorable prognosis if radioiodine-negative tumor tissue, especially in distant metastases, is present. Also, these cancers are not detected by routine diagnostic work-up with radioactive iodine-131 scintigraphy and they cannot be treated efficiently by radioiodine therapy. Therefore, tumor cells continue to grow undetected and the chance of cure decreases significantly [4] ; hence the most effective therapy is surgical excision of these lesions.
18F-FDG PET is able to reveal iodine-negative tumor tissue with a diagnostic accuracy that is higher than that of other imaging modalities [7] . In this study, the diagnostic accuracy was 100% in detection of LRR. These values are within the range of the diagnostic accuracies that have been reported by other studies [6, 7, 14-16, 21, 22] . In fact FDG PET/CT leads to exact localization of hypermetabolic lesions resulting in higher diagnostic confidence, compared with each imaging modality alone "CT and PET" [23] [24] [25] [26] . Furthermore, pitfalls of PET are reduced using PET/CT [27] .
The main limitation of 18F-FDG PET is the possibility of false-positive 18F-FDG accumulations in the neck leading to false diagnosis of lymph node metastases and the potential scheduling of a futile operation [28, 29] . However, this was not the case in our study regarding the cervical region as experience and knowledge of normal physiological FDG uptake are established and well accounted by the interpretators as in FDG uptake in vocal cords that was misinterpreted in some of the studied cases in Palmedo et al. study [4] .
The main aspect of the study is evaluation of its therapeutic relevance of FDG PET/CT on the investigated patients. The optimal for patients with iodine-accumulating tumors is surgical removal followed by radioactive-iodine ablation [30] ; however this is appropriate if only iodinenegative tumors are present where complete surgical removal of iodine-negative tissue is the only curative treatment option [4] . Furthermore, it seems important to diagnose and remove iodine-negative tumor tissue as early as possible because prognosis of this tumor subgroup is essentially worse than that of the other scenarios of differentiated thyroid cancer [13, [31] [32] [33] .
FDG-PET can be used in patients with known iodinepositive tumor sites to localize coexisting additional iodinenegative tumor tissue that is FDG-positive [17] . If iodinenegative tumor sites exist in addition to iodine-positive sites, the benefit of further radioiodine therapy is questionable [17, 18] . In our study 6 patients received empirical high dose of radioactive iodine-131 with negative post-therapy scan. Though, it was reported that high-dose radioiodine therapy appears to have little or no effect on iodine-negative FDGavid metastatic lesions [34] , but in those patients we noticed maxSUV was ≤5 in FGD PET/CT and we consider them as of LMA that could be attributed to the presence of a less differentiated or mixed components of well and undifferentiated cancer tissues in the positive lesions, hence we decide to give empirical high-dose of radioactive iodine-131 and evaluate its potential usefulness. The latter was confirmed by the declined TG found in their follow-up however such lesions were beyond the scintigraphic resolution of post-therapy iodine-131 scan. In fact though post-therapy TG level was 6.8±1.4 ng/ml but this was acceptable as it was stated that: However, for further confirmation of our suggestion, further study with larger sample size should be performed on such a patient sub-group.
Other points of some concern are the limitations of our study; First: CT is usually performed without a contrast agent in such group. However, in patients with DTC, CT is generally done without the application of a contrast agent to avoid blockage of iodine uptake. This also applies to patients in whom iodine-negative tissue is suspected, because iodinenegative and iodine-positive tissue may coexist in one patient [4] . Second, the minimal time for follow-up of patients [18±6.2 months] through 18F-FDG avidity is a predictor of reduced survival [4, 35] ; hence our study did not determine the long term outcome of applied strategy of therapy.
Finally, we consider our suggestion regarding the cervical adenopathy with what we call LMA in DTC patients with negative iodine-131 scan and elevated TG could give the opportunity for I131 therapy in such patients from the start and avoidance of serious surgical morbidity if these lesions are located in the vicinity of critical structures as great vessels.
CONCLUSION
Integrated FDG PET/CT has an excellent diagnostic accuracy in a therapeutically relevant way in thyroid cancer patients with iodine-negative loco-regional recurrences by precisely localizing tumor tissue and guiding the clinical management of recurrent thyroid carcinoma and aids in the selection of appropriate salvage. What could be added from the current study is that those with LMA could benefit from further empirical high dose of RA-131 therapy as a less differentiated or a mixture of un-differentiated thyroid cancer cells could be present but further studies with a larger patients' number are needed to support this suggestion.
